{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:08:45Z","timestamp":1790086125759,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the science and technology department\u2019s major program of Henan, China","award":["161100311100"],"award-info":[{"award-number":["161100311100"]}]},{"name":"the national health and family planning commission in China","award":["201601010"],"award-info":[{"award-number":["201601010"]}]},{"name":"The education department\u2019s Project of Henan, China","award":["19A320052"],"award-info":[{"award-number":["19A320052"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>We evaluated the prognostic and diagnostic ability of p16\/Ki-67 immunocytochemistry, HPV E6\/E7 mRNA testing and HPV DNA assay in triaging ASCUS to find a way to manage cervical lesions more effectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a prospective study through follow-up. The detection methods of the three factors: p16\/Ki-67 immunocytochemistry conducted by using the CINtec\u00ae Plus Kit, E6\/E7 mRNA testing by QuantiVirus\u00aeHPV E6\/E7 mRNA assay and DNA by Hybrid Capture 2 assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred three women with ASCUS satisfied requirements and completed the entire follow-up process. All CIN2+ occurred in women who were mRNA positive at baseline, none in mRNA negative. 100% (6\/6) patients with CIN2+ were HPV DNA assay positive, 100% (6\/6) were HPV E6\/E7 mRNA testing positive and 50.0% (3\/6) were p16\/Ki-67 immunocytochemistry positive. The risk ratio of E6\/E7 mRNA test was 57.306 (95% CI 0.077\u201342,400.545). For endpoint of CIN2+, the sensitivity between HPV DNA assay and HPV E6\/E7 mRNA testing is no statistical difference, but statistical difference exists between HPV E6\/E7 mRNA testing vs. p16\/Ki-67 immunocytochemistry (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20095.718,<jats:italic>P<\/jats:italic>\u2009=\u20090.023) and HPV DNA assay vs. p16\/Ki-67 immunocytochemistry (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20095.718,<jats:italic>P<\/jats:italic>\u2009=\u20090.023). The specificity of E6\/E7 mRNA testing, p16\/Ki-67 and DNA assay in triaging ASCUS was 44.33, 75.26 and 11.34% respectively and is all statistical difference (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200926.277,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001(HPV DNA assay vs. HPV E6\/E7 mRNA testing),<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200919.297,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001(HPV E6\/E7 mRNA testing vs. p16\/Ki-67 immunocytochemistry),<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200980.707,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001(HPV DNA assay vs. p16\/Ki-67 immunocytochemistry). The expression level of 2097.09 copies\/ml was the optimal cut-off value for HPV E6\/E7 mRNA testing to diagnose CIN2+, the sensitivity and specificity was 61.1 and 68.2%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>High expression of HPV E6\/E7 mRNA could be a good candidate as a diagnostic biomarker to triage ASCUS superseding HPV DNA. p16\/Ki-67 immunocytochemistry is suggested to be a good tool to triage ASCUS, but it reduced the sensitivity of diagnosis when improves the diagnostic specificity.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12985-019-1251-4","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T16:03:17Z","timestamp":1574352197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prognostic and diagnostic validity of p16\/Ki-67, HPV E6\/E7 mRNA, and HPV DNA in women with ASCUS: a follow-up study"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3308-2447","authenticated-orcid":false,"given":"Chenchen","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"1251_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2018.10897","volume":"320","author":"SJ Curry","year":"2018","unstructured":"Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for cervical Cancer: US preventive services task force recommendation statement. JAMA. 2018;320:674\u201386.","journal-title":"JAMA."},{"key":"1251_CR2","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","volume":"287","author":"D Solomon","year":"2002","unstructured":"Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114\u20139.","journal-title":"JAMA."},{"key":"1251_CR3","doi-asserted-by":"crossref","first-page":"536495","DOI":"10.1155\/2014\/536495","volume":"2014","author":"X Catteau","year":"2014","unstructured":"Catteau X, Simon P, No\u00ebl JC. Evaluation of the oncogenic human papillomavirus DNA test with liquid-based cytology in primary cervical Cancer screening and the importance of the ASC\/SIL ratio: a Belgian study. ISRN Obstet Gynecol. 2014;2014:536495.","journal-title":"ISRN Obstet Gynecol"},{"issue":"Suppl 3","key":"1251_CR4","first-page":"S3\/78","volume":"24","author":"M Arbyn","year":"2006","unstructured":"Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(Suppl 3):S3\/78\u201389.","journal-title":"Vaccine."},{"key":"1251_CR5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.vaccine.2015.12.011","volume":"34","author":"M Fakhreldin","year":"2016","unstructured":"Fakhreldin M, Elmasry K. Improving the performance of reflex human papilloma virus (HPV) testing in triaging women with atypical squamous cells of undetermined significance (ASCUS): a restrospective study in a tertiary hospital in United Arab Emirates (UAE). Vaccine. 2016;34:823\u201330.","journal-title":"Vaccine."},{"key":"1251_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S1386-6532(09)70002-2","volume":"45 Suppl 1","author":"JT Cox","year":"2009","unstructured":"Cox JT. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol. 2009;45 Suppl 1:S3\u20133S12.","journal-title":"J Clin Virol"},{"key":"1251_CR7","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa071430","volume":"357","author":"MH Mayrand","year":"2007","unstructured":"Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579\u201388.","journal-title":"N Engl J Med"},{"key":"1251_CR8","doi-asserted-by":"crossref","unstructured":"ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393\u2013400.","DOI":"10.1067\/mob.2003.462"},{"key":"1251_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1086\/653826","volume":"202","author":"K Louvanto","year":"2010","unstructured":"Louvanto K, Rintala MA, Syrj\u00e4nen KJ, Gr\u00e9nman SE, Syrj\u00e4nen SM. Genotype-specific persistence of genital human papillomavirus (HPV) infections in women followed for 6 years in the Finnish family HPV study. J Infect Dis. 2010;202:436\u201344.","journal-title":"J Infect Dis"},{"key":"1251_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1155\/2001\/249506","volume":"17","author":"M von Knebel Doeberitz","year":"2001","unstructured":"von Knebel Doeberitz M. New molecular tools for efficient screening of cervical cancer. Dis Markers. 2001;17:123\u20138.","journal-title":"Dis Markers"},{"key":"1251_CR11","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0002-9440(10)65689-1","volume":"153","author":"T Sano","year":"1998","unstructured":"Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153:1741\u20138.","journal-title":"Am J Pathol"},{"key":"1251_CR12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.5858\/2007-131-1343-PAKIIA","volume":"131","author":"L Iaconis","year":"2007","unstructured":"Iaconis L, Hyjek E, Ellenson LH, Pirog EC. p16 and Ki-67 immunostaining in atypical immature squamous metaplasia of the uterine cervix: correlation with human papillomavirus detection. Arch Pathol Lab Med. 2007;131:1343\u20139.","journal-title":"Arch Pathol Lab Med"},{"key":"1251_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3802\/jgo.2008.19.3.162","volume":"19","author":"EJ Nam","year":"2008","unstructured":"Nam EJ, Kim JW, Hong JW, Jang HS, Lee SY, Jang SY, et al. Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. J Gynecol Oncol. 2008;19:162\u20138.","journal-title":"J Gynecol Oncol"},{"key":"1251_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.arcmed.2004.07.004","volume":"35","author":"MM Dabi\u0107","year":"2004","unstructured":"Dabi\u0107 MM, Hlupi\u0107 L, Babi\u0107 D, Juki\u0107 S, Seiwerth S. Comparison of polymerase chain reaction and catalyzed signal amplification in situ hybridization methods for human papillomavirus detection in paraffin-embedded cervical preneoplastic and neoplastic lesions. Arch Med Res. 2004;35:511\u20136.","journal-title":"Arch Med Res"},{"key":"1251_CR15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2217\/fmb.11.87","volume":"6","author":"VV Sahasrabuddhe","year":"2011","unstructured":"Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol. 2011;6:1083\u201398.","journal-title":"Future Microbiol"},{"key":"1251_CR16","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1158\/1078-0432.CCR-06-2881","volume":"13","author":"PE Castle","year":"2007","unstructured":"Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, Mitchell AL, et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6\/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res. 2007;13:2599\u2013605.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"1251_CR17","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/S1386-6532(09)70009-5","volume":"45","author":"J Dockter","year":"2009","unstructured":"Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol. 2009;45(Suppl 1):S55\u201361.","journal-title":"J Clin Virol"},{"key":"1251_CR18","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1158\/1055-9965.EPI-08-0508","volume":"17","author":"A Szarewski","year":"2008","unstructured":"Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomark Prev. 2008;17:3033\u201342.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1251_CR19","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-12-0270","volume":"18","author":"N Wentzensen","year":"2012","unstructured":"Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, et al. Performance of p16\/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012;18:4154\u201362.","journal-title":"Clin Cancer Res"},{"key":"1251_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jviromet.2013.10.032","volume":"196","author":"TY Liu","year":"2014","unstructured":"Liu TY, Xie R, Luo L, Reilly KH, He C, Lin YZ, et al. Diagnostic validity of human papillomavirus E6\/E7 mRNA test in cervical cytological samples. J Virol Methods. 2014;196:120\u20135.","journal-title":"J Virol Methods"},{"key":"1251_CR21","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1128\/JCM.00382-10","volume":"48","author":"S Ratnam","year":"2010","unstructured":"Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, et al. Clinical performance of the PreTect HPV-proofer E6\/E7 mRNA assay in comparison with that of the hybrid capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol. 2010;48:2779\u201385.","journal-title":"J Clin Microbiol"},{"key":"1251_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124460","volume":"10","author":"H Johansson","year":"2015","unstructured":"Johansson H, Bjelkenkrantz K, Darlin L, Dilllner J, Forslund O. Presence of high-risk HPV mRNA in relation to future high-grade lesions among high-risk HPV DNA positive women with minor cytological abnormalities. PLoS One. 2015;10:e0124460.","journal-title":"PLoS One"},{"key":"1251_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057600","volume":"8","author":"P Giorgi Rossi","year":"2013","unstructured":"Giorgi Rossi P, Benevolo M, Vocaturo A, Caraceni D, Ciccocioppo L, Frega A, et al. Prognostic value of HPV E6\/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: a follow-up study. PLoS One. 2013;8:e57600.","journal-title":"PLoS One"},{"key":"1251_CR24","doi-asserted-by":"crossref","first-page":"21181","DOI":"10.18632\/oncotarget.8307","volume":"7","author":"LL Yu","year":"2016","unstructured":"Yu LL, Chen W, Lei XQ, Qin Y, Wu ZN, Pan QJ, et al. Evaluation of p16\/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China. Oncotarget. 2016;7:21181\u20139.","journal-title":"Oncotarget."},{"key":"1251_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ygyno.2010.06.011","volume":"119","author":"M Reuschenbach","year":"2010","unstructured":"Reuschenbach M, Clad A, von Knebel DC, Wentzensen N, Rahmsdorf J, Schaffrath F, et al. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol. 2010;119:98\u2013105.","journal-title":"Gynecol Oncol"},{"key":"1251_CR26","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1158\/1055-9965.EPI-08-0306","volume":"17","author":"K Cuschieri","year":"2008","unstructured":"Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomark Prev. 2008;17:2536\u201345.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1251_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/1471-0528.13076","volume":"122","author":"A Kisser","year":"2015","unstructured":"Kisser A, Zechmeister-Koss I. A systematic review of p16\/Ki-67 immuno-testing for triage of low grade cervical cytology. BJOG. 2015;122:64\u201370.","journal-title":"BJOG."},{"key":"1251_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00404-017-4588-1","volume":"297","author":"C Ren","year":"2018","unstructured":"Ren C, Zhu Y, Yang L, Zhang X, Liu L, Ren C. Diagnostic performance of HPV E6\/E7 mRNA assay for detection of cervical high-grade intraepithelial neoplasia and cancer among women with ASCUS Papanicolaou smears. Arch Gynecol Obstet. 2018;297:425\u201332.","journal-title":"Arch Gynecol Obstet"},{"key":"1251_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1631\/jzus.B1600288","volume":"18","author":"YL Yao","year":"2017","unstructured":"Yao YL, Tian QF, Cheng B, Cheng YF, Ye J, Lu WG. Human papillomavirus (HPV) E6\/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women. J Zhejiang Univ Sci B. 2017;18:256\u201362.","journal-title":"J Zhejiang Univ Sci B"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-019-1251-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-019-1251-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-019-1251-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T16:45:29Z","timestamp":1665074729000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-019-1251-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1251"],"URL":"https:\/\/doi.org\/10.1186\/s12985-019-1251-4","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"29 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and approved by the Ethics Committee of The Third Affiliated Hospital of Zhengzhou University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}